Gut Microbiota Influence on Cardiovascular Health

The human gastrointestinal tract hosts a vast community of microorganisms whose metabolic activities extend far beyond digestion, exerting profound effects on vascular integrity, cardiac function and systemic inflammation. Gut microbes generate bioactive compounds—including short-chain fatty acids, secondary bile acids and trimethylamine N-oxide (TMAO)—that can modulate endothelial function, lipid metabolism and immune responses. Dysbiosis, or disruption of microbial balance, has been linked to the initiation and progression of atherosclerotic plaque, hypertension, arrhythmias and heart failure. Mechanistically, microbial metabolites may influence cholesterol handling, promote oxidative stress and engage pro-inflammatory signalling cascades, while microbial antigens can prime immune cells and alter host gene expression. Understanding these pathways has revealed novel biomarkers and suggested therapeutic strategies—such as dietary intervention, prebiotics, probiotics and enzyme inhibitors—to restore microbial equilibrium and mitigate cardiovascular risk on a global scale.

Research from Nature Portfolio

Recent foundational work has identified flavin-containing monooxygenase 3 (FMO3) as a critical host enzyme that bridges insulin signalling, gut-derived trimethylamine and vascular pathology. In models of insulin resistance, suppression of FMO3 reduced the conversion of microbial trimethylamine into TMAO, resulting in decreased hyperglycaemia, hyperlipidaemia and atherosclerotic lesion formation. These findings reveal a direct enzymatic link between host metabolism and microbial by-products, highlighting FMO3 modulation as a promising target to attenuate cardiometabolic dysfunction.

Gut Microbiota Influence on Cardiovascular Health publication trend

The graph below shows the total number of articles in gut microbiota influence on cardiovascular health across all publications each year (not limited to Nature Index journals).

Technical terms

Gut microbiota: The community of bacteria, archaea, fungi and viruses inhabiting the gastrointestinal tract.

Trimethylamine N-oxide (TMAO): A metabolite produced by host oxidation of microbial trimethylamine, associated with pro-atherogenic effects.

Flavin-containing monooxygenase 3 (FMO3): A liver enzyme that converts trimethylamine to TMAO and links microbial metabolism with host insulin signalling.

Atherosclerosis: Chronic arterial disease characterised by lipid accumulation and inflammatory cell infiltration within vessel walls.

Metagenomics: A sequencing approach for analysing the collective genetic material of entire microbial communities without the need for culture.

Atrial fibrillation: A common cardiac arrhythmia marked by disordered electrical activity in the atria, increasing stroke and heart-failure risk.

Pulmonary hypertension: Elevated arterial pressure in the lungs that places strain on the right ventricle and impairs cardiac output.

References

1. Promising dawn in the management of pulmonary hypertension: The mystery veil of gut microbiota. iMeta (2024).
2. The correlation between gut microbiome and atrial fibrillation: pathophysiology and therapeutic perspectives. Military Medical Research (2023).
3. Platelet amino acid spectrum and gut microbiota, their links in patients with coronary artery disease and atrial fibrillation. Gastroenterology (2023).
4. Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB. Journal of the American Heart Association (2016).
5. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nature Communications (2015).